Hereditary spastic paraparesis type 18 (SPG18): new ERLIN2 variants in a series of Italian patients, shedding light upon genetic and phenotypic variability.
Amyotrophic lateral sclerosis
Hereditary spastic paraparesis
Negative dominance
Phenoconversion
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
01 Mar 2024
01 Mar 2024
Historique:
received:
16
01
2024
accepted:
19
02
2024
medline:
1
3
2024
pubmed:
1
3
2024
entrez:
1
3
2024
Statut:
aheadofprint
Résumé
Hereditary spastic paraparesis (HSP) is a group of central nervous system diseases primarily affecting the spinal upper motor neurons, with different inheritance patterns and phenotypes. SPG18 is a rare, early-onset, complicated HSP, first reported as linked to biallelic ERLIN2 mutations. Recent cases of late-onset, pure HSP with monoallelic ERLIN2 variants prompt inquiries into the zygosity of such genetic conditions. The observed relationship between phenotype and mode of inheritance suggests a potential dominant negative effect of mutated ERLIN2 protein, potentially resulting in a milder phenotype. This speculation suggests that a wider range of HSP genes could be linked to various inheritance patterns. With documented cases of HSP loci exhibiting both dominant and recessive patterns, this study emphasizes that the concept of zygosity is no longer a limiting factor in the establishment of molecular diagnoses for HSP. Recent cases have demonstrated phenoconversion in SPG18, from HSP to an amyotrophic lateral sclerosis (ALS)-like syndrome. This report highlights two cases out of five exhibiting HSP-ALS phenoconversion, discussing an observed prevalence in autosomal dominant SPG18. Additionally, the study emphasizes the relatively high incidence of the c.502G>A variant in monoallelic SPG18 cases. This mutation appears to be particularly common in cases of HSPALS phenoconversion, indicating its potential role as a hotspot for a distinctive SPG18 phenotype with an ALS-like syndrome. Clinicians need to be aware that patients with HSP may show ALS signs and symptoms. On the other hand, HSP panels must be included in genetic testing methods for instances of familial ALS.
Sections du résumé
INTRODUCTION
BACKGROUND
Hereditary spastic paraparesis (HSP) is a group of central nervous system diseases primarily affecting the spinal upper motor neurons, with different inheritance patterns and phenotypes. SPG18 is a rare, early-onset, complicated HSP, first reported as linked to biallelic ERLIN2 mutations. Recent cases of late-onset, pure HSP with monoallelic ERLIN2 variants prompt inquiries into the zygosity of such genetic conditions. The observed relationship between phenotype and mode of inheritance suggests a potential dominant negative effect of mutated ERLIN2 protein, potentially resulting in a milder phenotype. This speculation suggests that a wider range of HSP genes could be linked to various inheritance patterns.
PURPOSE AND BACKGROUND
OBJECTIVE
With documented cases of HSP loci exhibiting both dominant and recessive patterns, this study emphasizes that the concept of zygosity is no longer a limiting factor in the establishment of molecular diagnoses for HSP. Recent cases have demonstrated phenoconversion in SPG18, from HSP to an amyotrophic lateral sclerosis (ALS)-like syndrome.
METHODS AND RESULTS
RESULTS
This report highlights two cases out of five exhibiting HSP-ALS phenoconversion, discussing an observed prevalence in autosomal dominant SPG18. Additionally, the study emphasizes the relatively high incidence of the c.502G>A variant in monoallelic SPG18 cases. This mutation appears to be particularly common in cases of HSPALS phenoconversion, indicating its potential role as a hotspot for a distinctive SPG18 phenotype with an ALS-like syndrome.
CONCLUSIONS
CONCLUSIONS
Clinicians need to be aware that patients with HSP may show ALS signs and symptoms. On the other hand, HSP panels must be included in genetic testing methods for instances of familial ALS.
Identifiants
pubmed: 38427163
doi: 10.1007/s10072-024-07423-w
pii: 10.1007/s10072-024-07423-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Salinas S, Proukakis C, Crosby A, Warner TT (2008) Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol 7:1127–1138. https://doi.org/10.1016/S1474-4422(08)70258-8
doi: 10.1016/S1474-4422(08)70258-8
pubmed: 19007737
Lo Giudice T, Lombardi F, Santorelli FM et al (2014) Hereditary spastic paraplegia: clinical-genetic characteristics and evolving molecular mechanisms. Exp Neurol 261:518–539. https://doi.org/10.1016/j.expneurol.2014.06.011
doi: 10.1016/j.expneurol.2014.06.011
pubmed: 24954637
Finsterer J, Löscher W, Quasthoff S et al (2012) Hereditary spastic paraplegias with autosomal dominant, recessive, X-linked, or maternal trait of inheritance. J Neurol Sci 318:1–18. https://doi.org/10.1016/j.jns.2012.03.025
doi: 10.1016/j.jns.2012.03.025
pubmed: 22554690
de Souza PVS, de Rezende Pinto WBV, de Rezende Batistella GN et al (2017) Hereditary spastic paraplegia: clinical and genetic hallmarks. Cerebellum 16:525–551. https://doi.org/10.1007/s12311-016-0803-z
doi: 10.1007/s12311-016-0803-z
pubmed: 27271711
Harding AE (1981) Hereditary “pure” spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry 44:871–883. https://doi.org/10.1136/jnnp.44.10.871
doi: 10.1136/jnnp.44.10.871
pubmed: 7310405
pmcid: 491171
Lallemant-Dudek P, Durr A (2021) Clinical and genetic update of hereditary spastic paraparesis. Revue Neurologique 177:550–556. https://doi.org/10.1016/j.neurol.2020.07.001
doi: 10.1016/j.neurol.2020.07.001
pubmed: 32807405
Hedera P (1993) Hereditary spastic paraplegia overview. In: Adam MP, Mirzaa GM, Pagon RA, et al (eds) GeneReviews®. University of Washington, Seattle, Seattle (WA)
Browman DT, Resek ME, Zajchowski LD, Robbins SM (2006) Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER. J Cell Sci 119:3149–3160. https://doi.org/10.1242/jcs.03060
doi: 10.1242/jcs.03060
pubmed: 16835267
Lu JP, Wang Y, Sliter DA et al (2011) RNF170 protein, an endoplasmic reticulum membrane ubiquitin ligase, mediates inositol 1,4,5-trisphosphate receptor ubiquitination and degradation. J Biol Chem 286:24426–24433. https://doi.org/10.1074/jbc.M111.251983
doi: 10.1074/jbc.M111.251983
pubmed: 21610068
pmcid: 3129221
Al-Yahyaee S, Al-Gazali LI, De Jonghe P et al (2006) A novel locus for hereditary spastic paraplegia with thin corpus callosum and epilepsy. Neurology 66:1230–1234. https://doi.org/10.1212/01.wnl.0000208501.52849.dd
doi: 10.1212/01.wnl.0000208501.52849.dd
pubmed: 16636240
Yıldırım Y, Orhan EK, Iseri SAU et al (2011) A frameshift mutation of ERLIN2 in recessive intellectual disability, motor dysfunction and multiple joint contractures. Hum Mol Genet 20:1886–1892. https://doi.org/10.1093/hmg/ddr070
doi: 10.1093/hmg/ddr070
pubmed: 21330303
Alazami AM, Adly N, Al Dhalaan H, Alkuraya FS (2011) A nullimorphic ERLIN2 mutation defines a complicated hereditary spastic paraplegia locus (SPG18). Neurogenetics 12:333–336. https://doi.org/10.1007/s10048-011-0291-8
doi: 10.1007/s10048-011-0291-8
pubmed: 21796390
pmcid: 3215864
Al-Saif A, Bohlega S, Al-Mohanna F (2012) Loss of ERLIN2 function leads to juvenile primary lateral sclerosis. Ann Neurol 72:510–516. https://doi.org/10.1002/ana.23641
doi: 10.1002/ana.23641
pubmed: 23109145
Wakil SM, Bohlega S, Hagos S et al (2013) A novel splice site mutation in ERLIN2 causes hereditary spastic paraplegia in a Saudi family. Eur J Med Genet 56:43–45. https://doi.org/10.1016/j.ejmg.2012.10.003
doi: 10.1016/j.ejmg.2012.10.003
pubmed: 23085305
Tian W-T, Shen J-Y, Liu X-L et al (2016) Novel mutations in endoplasmic reticulum lipid raft-associated protein 2 gene cause pure hereditary spastic paraplegia type 18. Chin Med J 129:2759–2761. https://doi.org/10.4103/0366-6999.193444
doi: 10.4103/0366-6999.193444
pubmed: 27824013
pmcid: 5126172
Rydning SL, Dudesek A, Rimmele F et al (2018) A novel heterozygous variant in ERLIN2 causes autosomal dominant pure hereditary spastic paraplegia. Eur J Neurol 25:943-e71. https://doi.org/10.1111/ene.13625
doi: 10.1111/ene.13625
pubmed: 29528531
Srivastava S, D’Amore A, Cohen JS et al (2020) Expansion of the genetic landscape of ERLIN2-related disorders. Ann Clin Transl Neurol 7:573–578. https://doi.org/10.1002/acn3.51007
doi: 10.1002/acn3.51007
pubmed: 32147972
pmcid: 7187699
Park J-M, Lee B, Kim J-H et al (2020) An autosomal dominant ERLIN2 mutation leads to a pure HSP phenotype distinct from the autosomal recessive ERLIN2 mutations (SPG18). Sci Rep 10:3295. https://doi.org/10.1038/s41598-020-60374-y
doi: 10.1038/s41598-020-60374-y
pubmed: 32094424
pmcid: 7039913
Chen S, Zou J, He S et al (2021) More autosomal dominant SPG18 cases than recessive? The first AD-SPG18 pedigree in Chinese and literature review. Brain and Behavior 11:e32395. https://doi.org/10.1002/brb3.2395
doi: 10.1002/brb3.2395
pubmed: 34734492
pmcid: 8671789
Amador M-D-M, Muratet F, Teyssou E et al (2019) Spastic paraplegia due to recessive or dominant mutations in ERLIN2 can convert to ALS. Neurol Genet 5:e374. https://doi.org/10.1212/NXG.0000000000000374
doi: 10.1212/NXG.0000000000000374
pubmed: 32042907
pmcid: 6927358
Klebe S, Stevanin G, Depienne C (2015) Clinical and genetic heterogeneity in hereditary spastic paraplegias: From SPG1 to SPG72 and still counting. Revue Neurologique 171:505–530. https://doi.org/10.1016/j.neurol.2015.02.017
doi: 10.1016/j.neurol.2015.02.017
pubmed: 26008818
D’Amore A, Tessa A, Casali C et al (2018) Next generation molecular diagnosis of hereditary spastic paraplegias: an Italian cross-sectional study. Front Neurol 9:981. https://doi.org/10.3389/fneur.2018.00981
doi: 10.3389/fneur.2018.00981
pubmed: 30564185
pmcid: 6289125
Nasreddine ZS, Phillips NA, Bédirian V et al (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 53:695–699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
doi: 10.1111/j.1532-5415.2005.53221.x
pubmed: 15817019
Torella A, Ricca I, Piluso G et al (2023) A new genetic cause of spastic ataxia: the p.Glu415Lys variant in TUBA4A. J Neurol 270:5057–5063. https://doi.org/10.1007/s00415-023-11816-w
doi: 10.1007/s00415-023-11816-w
pubmed: 37418012
pmcid: 10511369
Richards S, Aziz N, Bale S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Travaglini L, Aiello C, Stregapede F et al (2018) The impact of next-generation sequencing on the diagnosis of pediatric-onset hereditary spastic paraplegias: new genotype-phenotype correlations for rare HSP-related genes. Neurogenetics 19:111–121. https://doi.org/10.1007/s10048-018-0545-9
doi: 10.1007/s10048-018-0545-9
pubmed: 29691679
Morais S, Raymond L, Mairey M et al (2017) Massive sequencing of 70 genes reveals a myriad of missing genes or mechanisms to be uncovered in hereditary spastic paraplegias. Eur J Hum Genet 25:1217–1228. https://doi.org/10.1038/ejhg.2017.124
doi: 10.1038/ejhg.2017.124
pubmed: 28832565
pmcid: 5643959
Wright FA, Bonzerato CG, Sliter DA, Wojcikiewicz RJH (2018) The erlin2 T65I mutation inhibits erlin1/2 complex-mediated inositol 1,4,5-trisphosphate receptor ubiquitination and phosphatidylinositol 3-phosphate binding. J Biol Chem 293:15706–15714. https://doi.org/10.1074/jbc.RA118.004547
doi: 10.1074/jbc.RA118.004547
pubmed: 30135210
pmcid: 6177578
Sánchez-Ferrero E, Coto E, Beetz C et al (2013) SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p. A510V. Clin Genet 83:257–262. https://doi.org/10.1111/j.1399-0004.2012.01896.x
doi: 10.1111/j.1399-0004.2012.01896.x
pubmed: 22571692
Coutelier M, Goizet C, Durr A et al (2015) Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain 138:2191–2205. https://doi.org/10.1093/brain/awv143
doi: 10.1093/brain/awv143
pubmed: 26026163
pmcid: 4553756
Khan TN, Klar J, Tariq M et al (2014) Evidence for autosomal recessive inheritance in SPG3A caused by homozygosity for a novel ATL1 missense mutation. Eur J Hum Genet 22:1180–1184. https://doi.org/10.1038/ejhg.2014.5
doi: 10.1038/ejhg.2014.5
pubmed: 24473461
pmcid: 4169543
Boutry M, Morais S, Stevanin G (2019) Update on the genetics of spastic paraplegias. Curr Neurol Neurosci Rep 19:18. https://doi.org/10.1007/s11910-019-0930-2
doi: 10.1007/s11910-019-0930-2
pubmed: 30820684
Fink JK (2001) Progressive spastic paraparesis: hereditary spastic paraplegia and its relation to primary and amyotrophic lateral sclerosis. Semin Neurol 21:199–207. https://doi.org/10.1055/s-2001-15265
doi: 10.1055/s-2001-15265
pubmed: 11442328
Silani V, Corcia P, Harms MB et al (2020) Genetics of primary lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 21:28–34. https://doi.org/10.1080/21678421.2020.1837177
doi: 10.1080/21678421.2020.1837177
pubmed: 33602012
Strong MJ, Gordon PH (2005) Primary lateral sclerosis, hereditary spastic paraplegia and amyotrophic lateral sclerosis: discrete entities or spectrum? Amyotroph Lateral Scler Other Motor Neuron Disord 6:8–16. https://doi.org/10.1080/14660820410021267
doi: 10.1080/14660820410021267
pubmed: 16036421
Osmanovic A, Widjaja M, Förster A et al (2020) SPG7 mutations in amyotrophic lateral sclerosis: a genetic link to hereditary spastic paraplegia. J Neurol 267:2732–2743. https://doi.org/10.1007/s00415-020-09861-w
doi: 10.1007/s00415-020-09861-w
pubmed: 32447552
pmcid: 7419373
Simone M, Trabacca A, Panzeri E et al (2018) KIF5A and ALS2 variants in a family with hereditary spastic paraplegia and amyotrophic lateral sclerosis. Front Neurol 9:1078. https://doi.org/10.3389/fneur.2018.01078
doi: 10.3389/fneur.2018.01078
pubmed: 30581417
pmcid: 6293196
Nicolas A, Kenna KP, Renton AE et al (2018) Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron 97:1268-1283.e6. https://doi.org/10.1016/j.neuron.2018.02.027
doi: 10.1016/j.neuron.2018.02.027
pubmed: 29566793
pmcid: 5867896
Branchu J, Boutry M, Sourd L et al (2017) Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. Neurobiol Dis 102:21–37. https://doi.org/10.1016/j.nbd.2017.02.007
doi: 10.1016/j.nbd.2017.02.007
pubmed: 28237315
pmcid: 5391847
Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17:94–102. https://doi.org/10.1016/S1474-4422(17)30401-5
doi: 10.1016/S1474-4422(17)30401-5
pubmed: 29154141
Saffari A, Kellner M, Jordan C et al (2023) The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15. Brain 146:2003–2015. https://doi.org/10.1093/brain/awac391
doi: 10.1093/brain/awac391
pubmed: 36315648
Musacchio T, Zaum A-K, Üçeyler N et al (2017) ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. J Neurol 264:11–20. https://doi.org/10.1007/s00415-016-8301-2
doi: 10.1007/s00415-016-8301-2
pubmed: 27738760
Rainier S, Bui M, Mark E et al (2008) Neuropathy target esterase gene mutations cause motor neuron disease. Am J Hum Genet 82:780–785. https://doi.org/10.1016/j.ajhg.2007.12.018
doi: 10.1016/j.ajhg.2007.12.018
pubmed: 18313024
pmcid: 2427280